

## DAFTAR KEPUSTAKAAN

- Ali S, Srivastava A, Chopra R. IL12B SNP and copy number varian type in IL23R gen associate with susceptibility to leprosy. J Med Genetic.2012.
- Ali S, Vollard A, Wijaya S, et al. PARK2/PACRG polimorfisme and susceptibility to typhoid and parathyphoid fever. Clin Exp Immunol. 2006;144:425-31.
- Alter A, Grant A, Abel L, Alcais A, Schurr E. Leprosy as genetic disease. Mamm Genome 2011;22:19-31.
- Alves L, de Mendonca Lima L, da Silva Maeda E, et al. *Mycobacterium leprae* infection of human Schwann cells depends on selective host kinases and pathogen-modulated endocytic pathways. FEMS Microbiol Lett. 2004; 238:429-37.
- Auphan N, Didonato J, Rosette C, Helmbertg A, Karin M. Molecular basis for immunosuppression by glucocorticoids: inhibition of NF- $\kappa$ B activity through induction of I $\kappa$ B synthesis. Science. 1995;270:286-90.
- Bakker MI, May L, Hatta M, Kwenang A, Klatser PR, Oskam L. Epidemiology of leprosy on five isolated islands in the Flores sea, Indonesia. Trop Med Int Health. 2002;7(9):780 -7.
- Bokhary M, Phung TL. Molecular pathogenesis of leprosy. Curr Trop Med Rep. Springer International Publishing. Published on line : 24 oktober 2016.
- Beste DJ, Laing E, Bonde B, Avignone-Rossa C, Bushell ME, Mc Fadden JJ. Transcriptomic analysis identitas growth rate modulation asa componen of the adaptation of mybacteria to survival inside the macrofage. J Bacteriol. 2007;189 (11) : 3969-76.
- Bakijo-Kansuo A, Mulic R, Boraska V, et al. Leprosy epidemic during history increased protective allele frequency of PARK2/PACRG genes in the population of the Mljed island, Croatia.EJMG. 2011;54:548-52.
- Beg AA, Baldwin AS. The I $\kappa$ B proteins: multifunctional regulators of Rel/NF- $\kappa$ B transcription factors. Genes Dev. 1993;7:2064-70.
- Bhat RM, Prakash C. Leprosy: An overview of pathophysiology. Interdiscip Perspect Infect Dis. 2012;2;1-6.
- Boggild AK, Correia JD, Keystone JS, Kain KC. Leprosy in Toronto : An analysis of 184 imported cases. JAMC. 2004;170;55-9.
- Bouchud PY, Nawn TR, Siddiqri MR, Sauderson P, Briffin S, Abraham I. Toll-like Receptor 2 (TLR2) polimorfisme and assciated with RR in Leprosy. J Infect Dis. 2008;197(2):253-61.

Brandsma JW, Cross H. Prevention of disability and ulcer care.in : Nunzi E, Massone C eds, Leprosy: A practical guide New York, Springer;1 st. 2012: 309-19.

Britton WJ, Lockwood DNJ. Leprosy, Lancet. 2004;363:1209-19.

Cook GC. Leprosy. In : Cook GC, Zumla A, editors. Mansons Tropical Disease. 21st ed. Edinburgh : Saunders. 2003:1065-84.

Chopra R, Shafat A, Amit KS, Shweta A, Bhupender K, Sidharta M, et al. Mapping of PARK2 and PACRG overlapping regulatory region reveals LD structure and functional variants in association with leprosy in unrelated Indian population groups. PLOS Gen. 2013;9: 1-13.

De Oca. Human polimorfisme as clinical predictors in leprosy. J Trop Med. 2011. Article ID 923943.

Elke Y, Anje C, Bob A, Sofie G, Lieve P, Guillaume L, et al. Acute injury in the peripheral nervous system triggers an alternative macrophage response. J Neuroinflammation. 2012;9:176.

Entezarmadi R, Majdzadeh R, Foroushani AR, et al. Inequality of leprosy disability in Iran, clinico or sosial economic inequality:An extended concentration indeks decomposition approach. Int J Prev Med. April 2014;5:414-23.

Fine PEM, Sterne JAC, Poninghaus JM, Bliss L, Saul j, Chihana A, et al. Household and dwelling contact as risk factors for leprosy in Northern Malawi. Am J Epidemiol. 1997;146(1):91-101.

Fitness J, Tosh K, Hill AV. Genetics of susceptibility to leprosy. Genes Immun. 2002;3:441-53.

Gardiner NJ. Integrin and the extracellular matrix: Key mediators of development and regeneration of sensory nervus system. Dev Neurobiol. 2011 Nov;71(11):1054-72.

Gilmore TD. Introduction to NF-(kappa)B: player, pathways, perpective. Oncogen.2006.oct 30:25(51):6680-4.

Goulart IM, Bernandes Souza DO, Marques CR, Pimenta VL, Goncalves MA, Goulart LR. Risk and protective factors for leprosy development determined by epidemiological surveillance of house hold contacts. Clin Vaccine Immunol. 2008; 15: 101-5.

Goulart LR, Goulart IM. Leprosy pathogenetic background: a review and lessons from other mycobacterial diseases. Arch Dermatol Res. Published online: 29 November 2008.

Graca CR, Tonelli-Nardi SM, Arcopaschoal VD. Update on genetics of leprosy. J Anc Dis Pre Rem. 2014; 2:1-6.

Gupta A, Sharma VK, Vohra H, Ganguly NK. Spontaneous apoptosis in peripheral blood mononuklear cell of leprosy patient:Role of cytokines. FEMS Immunology & Medical Microbiology. 1999; 24: 49-55.

Hristova VA, Brasley SA, Rylott RJ, Shaw GS. Identification of a novel Zn<sup>2+</sup> binding domain in the autosomal recessive juvenile parkinson related E3 ligase Parkin. *J Biol Chem.* 2009; 284(14): 978-86

Indropo A. *Immunologi Penyakit, MDVI.* 2001.

Jarduli LR, Sell AM, Reis PG, et al. Role of HLA, KIR, MICA, and cytokine genes in Leprosy. *Bio Med Res Int.* 2013. Diunduh dari : <http://dx.doi.org/10.1155/2013/989837>. Diakses tanggal 20 Maret 2016

Jamsari. *Penanda molekuler. Rekayasa genetika.* UR Press Pekanbaru. Badan Penerbit Universitas Riau. 2013. Cetakan pertama,78-114.

Jonathan B, Vagishurari M, Steven H, Niskit P, Ekroth N, Jennifer L, et al. NF- $\kappa$ B essential modulator deficiency leading to disseminated cutaneous atypical mycobacteria. *Mediterr J Hematol Infec Dis.* 2015; 7(1):e2015010.

Kementerian Kesehatan Republik Indonesia. 2014. *Pedoman nasional program pengendalian penyakit kusta.* Jakarta.

Kementerian Kesehatan Republik Indonesia. 2016. *Profil Kesehatan Indonesia 2015.* Jakarta.

Kosgei BK, Yun-peng L. Progress in research on immunological mechanisme of leprosy. *Asian Journal of medical sciences.* 2015;7:1-5.

Kresno SB. 2010. *Immunologi. Edisi ke 3.* Balai Penerbit Fakultas Kedokteran Universitas Indonesia, Jakarta.

Lahiri R, Randhawa B, Krahenbuhl J. Application of viability staining method for *Mycobacterium leprae* derived from the athymic (nu/nu) mouse footpad. *JMM.* 2005;54:235-42.

Lastoria JC, Abreu MMM. Leprosy: Review of the epidemiological, clinical, and etiopathogenic aspects. *An Bras Dermatol.* 2014;89(2):205-18.

Leseleuc L, Orlova M, Cobat A, Girard M, Thu Huong N, Ngoc Ba N et al., PARK2 mediates interleukin 6 and monocyte chemoattractant protein 1 production by human macrophages. *PLOS Neglected Tropical Disease.*2013;7:1-12.

Levis W, Gerogia B, Levis S, Park E. Deficient tumor necrosis factor- $\alpha$  production in lipoarabinomannan activated macrofages from toll-like reseptor-4 deficient mice: Implication for mycobacterial susceptibility. *Int J Lepr.* 2003;71(1):1-9.

Lockwood DNJ. Leprosy. In: Burns T, Breathnach S, Cox N, Griffiths C, eds. *Rook's textbook of dermatology*, 8th ed. United Kingdom:Wiley-Blackwell. 2010:321-19.

Malhotra D, Darvisk IK, Lohra RA, et al. Association Study of major risk single nucleotide polymorphisme in the common regulatory region by PARK2 and PACRG gens with leprosy in an Indian Population. *Eur J Derma Genet.* 2005;14:438-42.

- Manzanillo PS, Ayres JS, Watson RD, et al. PARKIN ubiquitin ligase mediated resistance to intracellular pathogens. *Nature*. 2013: 501.
- Mankar JM, Joshi SM, Velankar DH, Mhatre RK, Nalgunwar AN. A comparative study of the quality of life, knowledge, attitude and belief about leprosy disease among leprosy patients and community members in Shantivan Leprosy Rehabilitation Centre, Nere, Maharashtra, India. *Journal of Global Infectious Diseases*.2011;vol 3:378-382.
- Mira MT, Alexandre A, Nguyen VT, et al. Chromosome 6q25 is linked to susceptibility to leprosy in a Vietnam population. *Nat Genet*. 2003 Mar;33(3):412-5.
- Mira MT, Alcais A, Nguyen VT et al. Susceptibility to leprosy is associated with PARK2 and PACRG. *Nature* 2004;427:636-40.
- Mana M, Mahapolrus, Sarno EN, et al. Further biochemical characterization of *Mycobacterium leprae* larezin-binding protein. *Braz J Med Biol Res*. 2001 Apr;34(4):463-70.
- Massane C. Histopathology of the skin. In : Nunzi E, Massone C eds. *Leprosy: A practical guide* New York, Springer;1 st. 2012:115-136.
- Ministry of Health & Family Welfare, Government of India. 2005. *Burden disease of India*. New Delhi.
- Mantellini GG, Goncalves A, Padovani CR. Physical disabilities in leprosy: Some contemporary basic aspects. *J Mycobac Dis*. 2012; 2: 1-4.
- Merk CS, Cunha SS, Rodrigues LC. BCG vaccination and leprosy protection : review of current evidence and status of BCG in leprosy control. *Expert Rev vaccines*,2010;9:209-222.
- Moet FJ, Meima A, Oskam L, Richardus JH. Risk factors for the development of clinical leprosy among contacts and their relevance for targeted interventions. *Lepr Rev*.2004;75:310-26.
- Moet FJ, Pahan D, Schuring RP, Oskam L, Richardus JH. Physical distance, genetic relationship, age, and leprosy classification are independent risk factors for leprosy in contacts of patients with leprosy. *J Infect Dis*. 2006;193:346-53.
- Monot M, Honore N, Baliere C, Baohong J, Sow S, Brennan PJ. Are variable-number tandem repeats appropriate for genotyping *Mycobacterium leprae*. *J Clin Microbiol*.2008;46:2291-7.
- Moschella SL. An update on the diagnosis and treatment of leprosy. *J Am Acad Dermatol* 2004;51:417-26.
- Moraes MO, Cardoso CC, Vanderborcht PR, Pacheco AG. Genetic of host response in leprosy. *Lepr Rev*. 2006;77:189-202.

- Naafs B, Noto S. Reaction in leprosy. In : Nunzi E, Massone C, eds. *Leprosy: A practical guide*, 1st ed. New York, Springer. 2012:219-39.
- Nark UB, Naik UB, Mark S, Rao VP. Evaluation of significance of skin in leprosy for diagnosis, follow up, assesment of treatment outcome and relaps. *Asiat J Biotechnol Resour.* 2011;2(5) 547-52.
- Nath I, Chaduvulu M. Immunological aspects. In: *IAL textbook of leprosy*, 1<sup>st</sup> edition. Kar HK, Kumar B, eds. Jaypee Brother Medical Publishers (P) Ltd. 2010:60-73.
- Nauman M. Nuclear factor- activation and innate immune response in microbial pathogen infection. *Biochem Pharmacol.* 2000;60:1100-14.
- Neurath MF, Becker C, Barbulescu K. Role of NF- in immune and inflamation response in the gut. *Gut.* 1998;43(6):856-60.
- Noordeen SK. Epidemiology of leprosy. Dalam : Hasting RC, penyunting. *Leprosy*. Edisi ke 2. London : Churchill Livingstone;1994.29-43.
- Nunzi E, Massone C, Noto S. Clinical features. In : Nunzi E, Massone C, eds. *Leprosy: A practical guide* New York, Springer;1 st. 2012:75-110.
- Oliveira RB, Ochoa MT, Sieling PA, et al. Expression of toll like receptor 2 on human schwann cells : A mechanism of nerve damage in leprosy. *Infect Immun.* 2003 Mar;71(3):1427-33.
- Orlova M, Pietrantonio T, Schurr E. Genetic of infections diseases: Hidden etiologies and common pathways. *Clin Chem Lab Med.* 2011;49:1427-37.
- Ottenhoff THM. New insights and tools to combat leprosy nerve damage. *Lepr Rev.*2011;82:334-7.
- Palombella V, Rando O, Goldberg A, Maniatis T. 1994. The ubiquitin-proteasome pathway is required for processing the NF- $\kappa$ B precursor protein and the activation of NF- $\kappa$ B. *Cell.* 1994;78(5):773-85.
- Paul-Clark M, Mc Master S, Belcher E, Sorrentino R, Anandarajah J, Fleet M. Differential effects of Gram-positive versus Gram-negative bacteria on NOSII and TNF in macrophages: role of TLRs in synergy between the two. *British Journal of Pharmacology.* 2006;148:1067-75.
- Pereira RMS, Celegari-silva TC, Hernandez MD, et al. Mycobacterium leprae induces NF- $\kappa$ B-dependent transcription repression in human schwann cell. *Biochem Biophys Res Comm.* 2005; 335:20-6.
- Pinheiro RO, Sauzasales Jd, Sarpo EN, Sampaio EP. Mycobacterium leprae-host cell interaction and genetic determinated in Leprosy: An overview. *Future Microbiol.* 2011;6(2):217-30.

- Quaresma JAS, Almeida FAC, Aarao TLS, et al. Transforming growth factor- and apoptosis in leprosy skin lesions : Possible relationship with the control of the tissue immune response in the *Mycobacterium leprae* infection. *Microbes Infect.* 2012 Aug;14(9):696-701.
- Quaresma, Luiz W, Hellen TF, Rosana MFL, Carla P, Maria ISD. Immunohistochemical evaluation of macrophage activity and its relationship with apoptotic cell death in the polar forms of leprosy. *Microb Pathog.*2010;49(4):135-40.
- Rambukkana A, Zanassi G, Tapinos M, et al. Contact-dependent demyelination by *Mycobacterium leprae* in the absence of immune cells. *Science.* 2002; 296: 927-31.
- Rambukkana A. *Mycobacterium leprae* induced demyelination: A model for early nerve degeneration. *Curr Opin Immunol.* 2004;16:511-18.
- Rea TH, Modlin RL. Leprosy. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, eds. *Dermatology in general medicine.* 7th ed. New York: McGraw Hill. 2008:1787-96.
- Reinar LM, Forsetlund L, Bjordal A, Lockwood D. Interventions for skin changes caused by nerve damage in leprosy. *Cochrane Database Syst Rev.*2008;16(3): CD004833.
- Ren Zhang F, Dan Sun L, Xiao Yan X, Sheng Chu T, Qi Yu G, Qing Ski B,et al. Genome wide association study of leprosy. *NEJM.* 2009;361:2609-18.
- Richard W, Truman GJ, Ebenezer, et al.The armadillo as a model for peripheral neuropathy in leprosy. *ILAR Journal.* 2014;54(3):304-14.
- Richardus JH, Habbema JD. The impact of leprosy control on the transmission of *M. Leprae*: Is elimination being attained ?. *Lepr Rev.*2007;78:330-7.
- Rodrigues LS, Da silva Maeda E, Moreira ME, et al. *Mycobacterium leprae* induces insulin-like growth factor and promotes survival of Schwann cells upon serum withdrawal. *Cell Microbiol.*2010;12(1):42-54.
- Report of the International Leprosy Association, Technical forum, Paris, 2002.
- Sari N, Amiruddin MD, Amin S, Adam AM, Djamaluddin W, Vitayani S. Peran interleukin-2, interleukin-10, dan tumor necrosis factor- pada penyakit kusta. *MDVI.*2013;40(1):35-40.
- Sales AN, Leon AP, Dupre NC, Hacker MA, Nery JAC, Sarno EN et al. Leprosy among patient contacts : A multilevel study of risk factors. *Plos Neglected Tropical Diseases.* 2011;3:1-5.
- Sastroasmoro S, Ismael S. 2014. *Dasar – dasar metodologi klinis*, Jakarta : Sagung Seto,314.
- Schurr E, Alcais A, De Leseleuc L, Abel L. Genetic predisposition to leprosy: A major gene reveals novel pathway of immunity to *M.leprae*. *Sem Immunol* 2001;18:404–10.
- Scollard D. The biology of nerve injury in leprosy (Review). *Lepr Rev.* 2008;79: 242-53.

- Scollard D, Stryjewska B, Adams LB, et al. Epidemiology, microbiology, clinical manifestation, and diagnosis of leprosy. *Nature*. 2004.
- Siskawati Y, Menaldi SL, Soedarmi ESD. Penyakit kusta pada tiga bersaudara yang tinggal serumah. *MDVI*.2010;37(4):168-172.
- Shetty VP. Pathomechanisms of nerve damage. In: IAL textbook of leprosy, 1st edition. Kar HK, Kumar B, eds. Jaypee Brother Medical Publishers (P) Ltd. 2010:238-47.
- Shepard CC, McRae DH. A method for counting acid-fast bacteria. *International J of leprosy*.1968;36:78-82.
- Shen J, Wang Y, Zhou M, Li W. Anaysis on value of household contac survey in case detection of leprosy at a low endemic situation in China.2009;75:152-156.
- Shimoji Y, Vincent NG, Matsumurak, Fishty VA, Rambukkana A. A 21 Kd surface protein of *M. leprae* binds peripheral nork laminin 2 and mediated schwann sel invasion. *Proc Natl Acad Sci. USA*. 1999;96:9857-62.
- Siskawati Y, Menaldi SL, Sjamsoe-Daili ES. Penyakit kusta pada tiga bersaudara yang tinggal serumah. *Media Dermato-venereologica Indonesiana*. 2010; 37:168-72.
- Suneetha LM, Valdhini D, Suneetha S. Biochemical aspect of mycobacterium leprae binding protein : A review of their role in pathogenesis. *Int J Lepr*. 2001;69(4):341-8.
- Tarantino N, Tinevez JY, Crowel EF, et al. TNF and IL-1 exhibit distinct ubiquitin requirements for inducing NEMO-Ikk supramolecular structures. *J cell Bio*.2014;204(2):231-45.
- Terhorst D, Kalali B, Ollert M, Ring J, Mempel M. The role of toll-like receptors in host defenses and their relevance to dermatologic diseases. *Am J Clin Dermatol*. 2010;11:1-10.
- Tran TA, Nguyen AO, Chang J, Goldberg MS, Lee JK, Tangey MG. Lipopolysaccharida and tumor necrosis factor regulate parkin expression via nuklear factor – . *Plos One*. 2011;6(8):e23660.
- Truman RW, Singh P, Sharma R, et al. Probably zoonotic leprosy southern united states. *N Engl J Med* 2011; 364:1626-1633.
- Vasquez CMP, Netto RSM, Barbosa KBF, et al. Micronutrients influencing the immune response in leprosy. *Nutr Hosp*. 2014;29(1):26-36.
- Venkatesan K, Deo N. Biochemical aspects. In: IAL textbook of leprosy, 1<sup>st</sup> edition. Kar HK, Kumar B, eds. Jaypee Brother Medical Publishers (P) Ltd. 2010: 87-99.
- Walker SL, Lockwood DNJ. The clinical and immunological features of leprosy. *Br Med Bull*. Nov 2006;77-78:103-21.

Wang LW, Kimura A, Satoh R, Minaskita S. HLA linked with leprosy in Southern China  
HLA linked resistance alleles to leprosy. *Int J Lepr.* 2009;67(4):403 -8.

Wihastuti TA. Level of circulation endothelial cell and ekspresi of NFKB of human's perifer  
blood mononuclear cell in subjects with certain condition. 2011;

Wong SH, Gochhait WS, Malhotra D, et al. Leprosy and the adaptation of human toll-like  
receptor 1. *PLOS Pathogen.* Juli 2010;6. e1000979.

World Health Organization model prescribing information. *Drugs used in leprosy.* WHO  
Geneva:1998.

World Health Organization. *A guide to elimination leprosy as public health problem,*1st ed.  
WHO Geneva: 1995.





